Abstract
The function of astrocytes intertwines with the extracellular matrix, whose neuron and glial cell-derived components shape neuronal plasticity. Astrocyte abnormalities have been reported in the brain of the mouse model for fragile X syndrome (FXS), the most common cause of inherited intellectual disability, and a monogenic cause of autism spectrum disorder. We compared human FXS and control astrocytes generated from human induced pluripotent stem cells and we found increased expression of urokinase plasminogen activator (uPA), which modulates degradation of extracellular matrix. Several pathways associated with uPA and its receptor function were activated in FXS astrocytes. Levels of uPA were also increased in conditioned medium collected from FXS hiPSC-derived astrocyte cultures and correlated inversely with intracellular Ca\(^{2+}\) responses to activation of L-type voltage-gated calcium channels in human astrocytes. Increased uPA augmented neuronal phosphorylation of TrkB within the docking site for the phospholipase-C\(\gamma\)1 (PLC\(\gamma\)1), indicating effects of uPA on neuronal plasticity. Gene expression changes during neuronal differentiation preceding astrogenesis likely contributed to properties of astrocytes with FXS-specific alterations that showed specificity by not affecting differentiation of adenosine triphosphate (ATP)-responsive astrocyte

Ulla-Kaisa Peteri and Juho Pitkonen contributed equally to this study.
1 | INTRODUCTION

Astrocytes are important in neuronal maturation and synapse function via bidirectional astrocyte-neuron interactions (Durkee & Araque, 2019; Vasile et al., 2017; Verkrachtsky et al., 2014). They provide trophic support to neurons and contribute to brain homeostasis by regulating the extracellular environment. Astrocytes monitor and modulate synaptic transmission by controlling extracellular ion and neurotransmitter concentration in response to cytoplasmic Ca$^{2+}$ fluctuations (Südhof, 2018). Molecules produced and released from astrocytes and neurons form extracellular matrix structures, which play important role in cell migration, neurite outgrowth, synaptogenesis, and synaptic plasticity (Song & Dityatev, 2018).

Malfunction of astrocytes is associated with many brain disorders (Molofsky et al., 2012). Deficits of astrocytes are shown to contribute to impaired neuronal function in the brain of Fmr1 knockout (KO) mice, a mouse model of fragile X syndrome (FXS) (Simhal et al., 2019). The syndrome is the most common cause of inherited intellectual disability and a well-characterized monogenic form of autism spectrum disorder (ASD), with a prevalence around one in 4000 males and one in 8000 females (Crawford et al., 1999). The FXS phenotype includes hyperactivity, attention deficits, sensory integration problems, communication difficulties, poor motor coordination, social anxiety, and stereotyped patterns of behavior (Lozano et al., 2016; Terraciano et al., 2005). Epilepsy manifests in around 20% of cases (Berry-Kravis, 2002; Louhivuori et al., 2009) and criteria for ASD are fulfilled in 30%-54% of FXS males (Hageman et al., 2010). FXS results from the absence of the FMR1 protein (FMRP) caused by transcriptional silencing of the FMR1 gene with the expansion mutation comprising >200 cytosine-guanine-guanine (CGG) trinucleotide repeats (Colak et al., 2014). FMRP is an RNA-binding protein that is essential for normal synapse growth and function (Jin & Warren, 2000).

Coculturing Fmr1 KO neurons with wild type astrocytes rescues the abnormal dendritic phenotype (Jacobs & Doering, 2010), supporting the role for astrocytes in the pathophysiology of FXS. Selective absence of astroglial FMRP augments neuronal excitability, increases spine density in the motor cortex, and alters the mouse behavioral phenotype (Higashimori et al., 2013; Hodges et al., 2017). The plasminogen system is affected in the brain of Fmr1 KO mouse appearing increased expression of tissue plasminogen activator (tPA) in neural progenitors and astroglia (Achuta et al., 2014). Fmr1 KO astrocytes express less thrombospondin-1 (TSP-1) (Cheng et al., 2016) that is a matricellular protein, which can mediate synaptic recovery induced by urokinase-type plasminogen activator receptor (uPAR)-activated astrocytes (Diaz et al., 2017). Both uPAR and its ligand urokinase (uPA) are highly abundant in the developing central nervous system, and are activated in many disease states (Blasi & Carmeliet, 2002). Upon binding to uPAR, uPA catalyzes plasminogen activation, and plasmin generation as the initiation of the proteolysis cascade, but it also activates cell-signaling pathways involved in the regulation of differentiation, cellular adhesion, migration, and proliferation through non-plasminogenic mechanisms (Blasi & Carmeliet, 2002). Despite potential contribution of uPA/uPAR signaling to the extracellular matrix-linked pathophysiology in FXS (Wen et al., 2018), the signaling system has not been studied with respect to FMRP.

Patient-specific human induced pluripotent stem cells (hiPSC) that carry disease-specific information, differentiated toward the astrocyte lineage, provide an ideal human cell-based model to study disturbed molecular mechanisms in human astrocytes. The present study exploited hiPSC-derived astrocyte model to study alterations in human FXS astrocytes and revealed that uPA can act as a critical regulator of astrocyte function and astrocyte-neuron interactions in the absence of FMRP. The results demonstrate that uPA-linked astrocytic properties may contribute to patient-specific differences and prove useful when designing pharmacological interventions for neurodevelopmental disorders.

2 | MATERIALS AND METHODS

2.1 | Generation of human astrocytes

Human astrocytes were differentiated from single clones of hiPSC lines derived from FXS males (HEL69.6, HEL70.3, HEL70.6, and HEL100.2) and healthy male donors (HEL23.3, HEL24.3, HEL46.11, PO2/UEF-3A, and PO4/UEF-3B) characterized previously (Achuta et al., 2017; Achuta et al., 2018; Asikainen et al., 2015; Holmqvist et al., 2016; Trokovic et al., 2015). To avoid effects of genetic background, astrocytes were also differentiated from isogenic human embryonic stem cell (hESC) lines (Utami et al., 2020): control (H1) and FMR1KO carrying a fragile X mutation that was generated by CRISPR/Cas9 gene editing targeting exon 3 in the FMR1 gene. The research using human cells was approved by the Ethics Committee of the Hospital District of Helsinki and Uusimaa. All the human cell lines used in the study are listed in Table 1.

Human pluripotent stem cells (hPSCs) were maintained on Matrigel-coated plates in Essential 8 medium (E8; Thermo Fisher Scientific Ltd., Vantaa, Finland). Astrocytes were differentiated as
### 2.3 RNA sequencing analysis

RNA sequencing (RNA-seq) data were generated using triplicate samples of isogenic hPSC (H1 and FMR1KO cell lines)-derived cells at defined time points during astrocyte differentiation and NextSeq500 platform. The sequencing reads were filtered based on quality and length, and after adapter removal the reads were aligned to the human genome using Star Aligner (version 2.5.0b) and counted with high-throughput sequencing. We sequenced 20–30 millions reads per sample and aligned them using STAR v2.7.0 that uniquely mapped 80%–90% of the reads on the GRCh38 human genome, after quality trimming of 25 nucleotides from the 3'-ends of the transcripts (discarding reads shorter than 30 nucleotides) using cutadapt v1.8.1. Differential expression analysis was performed with the R package DESeq2 using a design formula that models the cell line difference at time 0, the difference over time, and any genotype-specific difference over time (by using the interaction term genotype: time). The likelihood ratio test removed any genotype-specific differences over time. Principal component analysis (PCA) showed six outliers (one replicate of undifferentiated cells, two at D30, and one at D95 of controls, and one iPSC FXS sample), which were removed from the analysis. Part of the genotype effect was visible on Component 2. The relative expression levels of control and FXS hPSC-derived cells at D12, D30, and D60 of differentiation to undifferentiated cells at D0 were compared and subjected to functional enrichment analysis performed with goset function from the gprofiler2 R package. Enrichment analysis performed with gost function from the gprofiler2 R package. Enrichment results was performed with the rvgo package (Sayols, 2020). In addition, comparison of the three D95 FXS samples to the two isogenic control samples was performed to detect genes whose final expression significantly differed. Follow-up analyses were performed with the clusterProfiler R package and included pathway enrichment analysis using the REACTOME database (Jassal et al., 2020) to assess significance by hypergeometric test and gene set enrichment analysis (GSEA) ranking genes by their statistics and using gene permutation of the ranked list for calculating the p-value of the enrichment scores.
2.4 | RNA extraction and RT-PCR

Total cellular RNA was extracted using NucleoSpin RNA kit (Qiagen) according to the manufacturer’s instructions and reverse-transcribed into complementary cDNA using iScript™ cDNA synthesis kit (Bio-Rad, #170-8891). Using cDNA as template, RT-quantitative polymerase chain reaction (qPCR) was performed with HOT FIREPol® EvaGreen® qPCR Mix Plus (Solis BioDyne) and LightCycler® 480 (Roche) for 45 cycles of 95°C for 15 s, 62°C for 20 s, and 72°C for 20 s. Gene expressions were analyzed with the ΔΔCt method using GAPDH expression and values from undifferentiated hiPSCs for normalization. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression was not affected by the absence of FMRP in transcriptome analysis of astrocytes (data not shown). Primer sequences are listed in Table 2.

2.5 | Astrocyte conditioned medium

For collection of astrocyte conditioned medium (ACM) cells were plated on Matrigel-coated T25 flasks at a density of 20,000 cells/cm² and grown for 7 days. On the day prior to the sample collection, medium was replaced with 5 ml of fresh neurosphere medium. As indicated cells were treated with all-trans retinoic acid (ATRA) for 24 h. Collected medium was filtered through a 0.22 μm filter and stored at –80°C until use.

2.6 | Analysis of plasminogen activators in ACM

The quantitative measurements of uPA and tPA in ACM were performed according to the manufacturer’s instructions using Abcam’s Enzyme-Linked Immunosorbent Assay (ELISA, Abcam) for human uPA (ab119611) and tPA (ab190812). The concentrations in diluted (1:1) culture medium were measured in duplicate, interpolated from the standard curve, and corrected for sample dilution.

2.7 | Protein isolation and Western blot analysis

Cells were isolated, suspended in ×1 RIPA lyes buffer (Upstate) supplemented with 1% protease inhibitor cocktail (Sigma), triturated, and centrifuged at ×10,000 g for 10 min at 4°C. Total protein (40 μg) was separated on SDS-polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane using Trans-Blot Turbo System (BioRad) and separated on SDS-polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane using Trans-Blot Turbo System (BioRad) and probed with rabbit polyclonal anti-FMRP antibody (1:500, ab17722; Abcam) at 4°C overnight after blocking with 5% nonfat dry milk in PBS at RT for 1 h. After washes, incubation with horseradish-peroxidase conjugated secondary antibody (1:10000, NA9340; GE Healthcare) was performed and immunoreactive protein was visualized using Pierce enhanced chemiluminescence (ECL) substrate (Thermo Fisher Scientific).

2.8 | Calcium imaging

For calcium imaging, astrocytes were plated on coverslips in a 12-well plate with 50,000 cells per well and imaging was performed on the following day as previously described (Achuta et al., 2018). Cells were loaded with 4 μM Fura-2 (HelloBio, HB0780) in Hepes-buffered medium (pH 7.4) containing 137 mM NaCl, 5 mM KCl, 0.44 KH₂PO₄, 4.2 mM NaHCO₃, 1 mM MgCl₂, 1 mM CaCl₂, and 10 mM glucose (all from Sigma-Aldrich) at 37°C for 30 min. The coverslip was then adjusted to SA-OLY/20 adapter and placed in the recording chamber with continuous perfusion with 37°C Hepes-buffered medium (2 ml/min). Cells were excited with 340 and 380 nm wavelengths and the emission was recorded at 505 nm. Cell somas were outlined as regions of interests (ROIs), and [Ca²⁺]i rise in each ROI was recorded. When recording high KCl-induced depolarization, NaCl was isosmotically replaced with 17 or 70 mM KCl. Anti-uPA antibody (1:2000, #119611, Abcam) and Nifedipine (10 μM, Sigma) were added as indicated. Using an Inverted IX70 microscope (Olympus Corporation, Hamburg, Germany) cells were visualized with (UApo/340) x10 air objective (Olympus) and images acquired with a Hamamatsu ORCA-Flash 4.0 camera. An image (ratio 340 nm/380 nm) was acquired each second and up to 100 cells were recorded simultaneously. Data analysis was performed using HCImage and Matlab.

2.9 | Analysis of TrkB phosphorylation

Primary cultures of cortical neurons were prepared from E18 rat embryos as described previously (Sahu et al., 2019). Cells were maintained in supplemented Neurobasal medium until D8 in vitro and incubated with pooled ACM from hiPSC-derived astrocytes supplemented with anti-uPA antibody (1:2000, #119611, Abcam) or TrkB.Fc (200 ng/ml; 688-TK, R&D Systems, Minneapolis, MN) as indicated for 30 min and lysed in neuronal progenitor lysis buffer (20 mM Tris–HCl; 137 mM NaCl; 10% glycerol; 50 mM NaF; 1% NP-40; 0.05 mM Na₂VO₃ containing a cocktail of protease and phosphatase inhibitors [#P2714 and #P0044, respectively, Sigma-Aldrich]). As a control test, rat cortical neurons were treated with recombiant rat urokinase protein (5 ng/ml, #92608, Abcam) for 1 h. The phosphorylation of different TrkB residues were determined by ELISA (Fred

| Gene  | Forward primer (5’-3’)       | Reverse primer (5’-3’)       |
|-------|-------------------------------|-------------------------------|
| GADPH | AACGACCCCCTTACATTGAC          | TCCACGACATAACTGAC             |
| PLAU  | GCCTTGTGAGATGCGGTTCC          | GGATCGTTATTACATCGGAGGGCA      |
| PLAUR | GGGTCTCAATGTGTTTCCA           | CAGAGTGACGCGGTTGAGG           |
| Serpine-1 | CTTGCAATGGGAAATGAGACCTTG     | CGAAATCATGTCACCTGTGTCAT       |

**TABLE 2** | Primers used in qPCR analysis
et al., 2019). Briefly, white 96-well plates (OptiPlate 96F-HB, Perkin Elmer) were coated with primary anti-TrkB antibody (1:1000, #AF1494, R&D Systems) in carbonate buffer (pH 9.8) overnight at 4°C. Following a blocking step with 3% BSA in PBST (137 mM NaCl, 10 mM phosphate, 2.7 mM KCl, 0.1% Tween-20; pH 7.4) for 2 h at RT, samples were incubated overnight at 4°C. The incubation with antibody against pTrkB Y816 (1:1000, #4168, Cell Signaling) or pTRKBY515 (1:1000, #9141, Cell Signaling) was followed by the incubation with HRP (horseradish peroxidase)-conjugated anti-Rb (#170–5046, Bio-Rad) for 2 h at RT. Finally, the chemiluminescent signal generated by the reaction with ECL substrate was analyzed in a plate reader (Varioskan Flash, Thermo Fisher Scientific).

2.10 | Statistical analysis

Data are means ± SEM. Statistical comparisons were performed with two-tailed Student’s unpaired t test, one-way ANOVA followed by post hoc Bonferroni test and Mann–Whitney test in analysis of [Ca²⁺], and two-way ANOVA and Fisher’s LSD post hoc test in TrkB phosphorylation experiments using IBM SPSS analysis software. A p-value of <.05 was considered statistically significant.

3 | RESULTS

3.1 | Differentiation of astrocytes modeling FXS

We used hPSC-derived forebrain astrocyte model (hASTRO) meaning astrocytes at D95 of differentiation in vitro (Peteri et al., 2020) to study putative alterations of human FXS astrocytes (Figure 1a). Differentiation of astrocytes followed the developmental processes of astrocytes from neuroepithelial induction and regional patterning using morphogens to progenitor expansion and astrocyte specification/maturation (Russ et al., 2021). We monitored the differentiation of isogenic FXS and control hESC-derived cells by RNA-seq transcriptomic analysis at D0, D12, D30, D60, and D95 of differentiation (Figure 1a). PCA analysis of lineage-specific marker expression and hierarchical clustering showed that undifferentiated cells clearly separated from clusters of differentiated cells (Figure 1b). FMRP-deficient and their isogenic control cells clustered together at all-time points (Figure 1b). At D95, both FXS and control hASTRO clustered together with previously published human astrocytes isolated from the embryonic brain and hiPSC-derived astrocytes generated with an alternative differentiation protocol (Figure 1b) (Magistri et al., 2016; Tcw et al., 2017).

Immunostaining of hASTRO generated from the isogenic FXS and control cell lines and also from four patient-specific FXS and four control hiPSCs demonstrated that over 90% of cells showed immunoreactivity for established astrocyte markers SOX9, NF1A, GFAP, and S100β (Figure 2a,b). Co-expression of GFAP and S100β was found in 98% of cells, suggesting that the hASTRO represented immature rather than mature astrocytes in the same way as the previously published hiPSC-derived astrocytes (Tcw et al., 2017). Astrocyte marker immunostaining of hASTRO suggested high purity of the astrocyte cultures. The number of MAP2 immunoreactive cells was less than 1% of total cells and the number of small MAP+ neuron-like cells did not differ between FXS and control hASTRO cultures (0.40 ± 0.42% in FXS and 0.48 ± 0.25% in control cultures) (Figure 2c). Western analysis confirmed that FXS hASTRO generated from both hiPSC lines with >200 CGG triplet repeats mutation in the FMR1 gene and from FMR1KO hESCs did not express FMRP (Figure 2d).

3.2 | Transcriptome analysis of FXS cells during astrocyte differentiation

Factors that are closely linked to control of neurogenesis induce gliogenesis (Takouda et al., 2017). Transcriptome analysis of
Differentiating isogenic neural progenitors lacking FMRP and their controls showed similar changes in the expression of factors that regulate the onset of gliogenesis and/or are known as early astrocyte markers (SOX9, NF1A, SLIT-1, FGF3, and GLI3) (Figure 3a). Transcriptome profiling also validated patterning of cells toward forebrain identity by increased expression of regional transcription factors (Rubenstein et al., 1998; Takouda et al., 2017) in both FXS and control cell cultures. Rostral genes FOXG1, LHX2, EMX1, and DLX1 were expressed similarly in high levels, while the midbrain-associated genes EN1, EN2, and FOXA2 and the hindbrain marker HOXA2 were expressed at very low levels during the differentiation of isogenic neural progenitors derived from FXS and control cell lines (Figure 3b).

In agreement with the previous studies showing altered differentiation of neural progenitors lacking FMRP (Achuta et al., 2017; Achuta et al., 2018; Boland et al., 2017; Li & Zhao, 2014; Telias & Ben-Yosef, 2014; Utami et al., 2020), comparison of the transcriptome of FXS neural progenitors to controls at D12 showed differential expression of several genes; altogether 3276 genes were differentially regulated (Figure 3c). Transcripts of 433 and 2843 genes were increased and reduced, respectively, in D12 neurospheres. Many of these genes (~24%) remained differentially regulated at D30 (Figure 3c). Functional annotation analysis revealed that biological processes related to nervous system development, synaptic signaling, and axonogenesis were activated in FXS neural progenitors at D30 (Figure 3d). The absence of FMRP suppressed several biological processes, including immune response, positive regulation of cytosolic calcium ion responses and cytokine production, response to other organism, and defense response, and activity of cell surface signaling pathway (Figure 3e). These gene expression changes in neural progenitors likely influenced differentiation of astrocytes with FXS-specific properties in vitro and presumably have impact on neurogenesis and gliogenesis in the developing FXS brain.

Comparison of RNA seq data of hESC-derived isogenic FXS and control hASTRO at D95 revealed 81 differentially regulated transcripts (Table 3). Genes implicated in the extracellular matrix organization were particularly enriched among the differentially regulated genes (Figure 4a). A strong enrichment for genes involved in integrin cell surface interaction was found ($p = .045$, $p$ adjusted = .0174, GSEA) in the gene ranking (Figure 4b). Enrichment of genes encoding proteins involved in the MET signaling cascade provided a potential
link to the pathophysiology of ASD. Genetic studies have associated the MET allele with ASD (Campbell et al., 2006) and MET signaling has been shown to be disrupted in ASD (Campbell et al., 2008). MET is a receptor tyrosine kinase that directly modulates WNT/β-catenin signaling (Kim et al., 2013) in line with the enrichment of transcripts of the WNT signaling pathway \((p=0.001, \text{ adjusted } p=0.0228, \text{ GSEA})\) in FXS hASTRO genes (Figure 4c). These results were consistent with previous studies showing that the WNT/β-catenin signaling pathway is affected and involved in altered fate specification of neural progenitors in FXS (Casingal et al., 2020; Luo et al., 2010).

Transcripts of several enriched genes \((p=0.0098, \text{ adjusted } p=0.0579, \text{ GSEA})\) in the upregulated portion of the FXS hASTRO transcriptome were linked to the plasminogen system that is also associated with MET signaling (Figure 5a). The RNA seq data suggested dysregulated expression of genes encoding uPA (PLAU), receptor for uPA (PLAUR), and plasminogen activator inhibitor-1, PAI-1 (SERPINE1), during differentiation of FXS hASTRO when compared with controls (Figure 5a,b). PAI-1 is a member of serine protease inhibitor (serpin) family and the principal inhibitor of uPA and tPA (see review Sillen & Declerck, 2021). From SERPINE2 and SERPINE3 paralogs, SERPINE2 was expressed in FXS and control hASTRO in the same way, while SERPINE3 expression was not detectable in astrocytes as reported previously (Lindner et al., 1986).

### 3.3 | Increased uPA mRNA expression in FXS astrocytes

We used hASTRO differentiated from four FXS male-derived hiPSC lines and three control cell lines to study alterations of plasminogen system in human FXS astrocytes in detail. The expression of PLAU had increased 3-fold \((p = 0.003)\) in hiPSC-derived FXS hASTRO compared with controls (Figure 5c). Expression of the gene encoding uPAR, PLAUR, was 1.2-fold higher in FXS hASTRO than in controls but the difference did not reach the level of significance \((p = 0.083)\) (Figure 5c). The mRNA expression of SERPINE1 showed high variation between biological samples, but the 5-fold reduction in the ratio of PLAU mRNA to SERPINE1 mRNA in FXS hASTRO suggested a crucial role for PAI-1 in the regulation of uPA function (Figure 5d).
| Id           | Base mean | log2FoldChange | lfcSE | stat | pval      | padj      | Gebe symbol |
|--------------|-----------|----------------|-------|------|-----------|-----------|-------------|
| ENSG00000187601 | 136.1     | −7.2           | 0.7   | −10.2| 2.0E-24   | 3.1E-20   | MAGEH1      |
| ENSG00000129824 | 362.2     | −12.2          | 1.3   | −9.8 | 8.2E-23   | 6.1E-19   | RPS4Y1      |
| ENSG00000165169 | 125.7     | −10.7          | 1.3   | −8.6 | 1.2E-17   | 6.3E-14   | DYNL3T      |
| ENSG00000102349 | 98.8      | −10.4          | 1.3   | −7.9 | 2.0E-15   | 7.8E-12   | KLF8        |
| ENSG00000181218 | 82.7      | −9.1           | 1.3   | −7.2 | 4.6E-13   | 1.4E-09   | H2AW        |
| ENSG00000196890 | 40.6      | −7.3           | 1.2   | −6.2 | 4.9E-10   | 1.3E-06   | H2B1U1      |
| ENSG00000000187601 | 136.1     | −7.2           | 0.7   | −10.2| 2.0E-24   | 3.1E-20   | MAGEH1      |
| ENSG00000129824 | 362.2     | −12.2          | 1.3   | −9.8 | 8.2E-23   | 6.1E-19   | RPS4Y1      |
| ENSG00000165169 | 125.7     | −10.7          | 1.3   | −8.6 | 1.2E-17   | 6.3E-14   | DYNL3T      |
| ENSG00000102349 | 98.8      | −10.4          | 1.3   | −7.9 | 2.0E-15   | 7.8E-12   | KLF8        |
| ENSG00000181218 | 82.7      | −9.1           | 1.3   | −7.2 | 4.6E-13   | 1.4E-09   | H2AW        |
3.4 | Increase in extracellular uPA in FXS astrocyte cultures

To examine secretion of uPA from human astrocytes, we assessed uPA protein levels in ACM collected from control and FXS hASTRO cultures. We found that uPA was increased 5.5-fold ($p = .018$) in ACM of FXS hASTRO (Figure 5e), suggesting that FXS hASTRO secreted more uPA. As a control, we treated astrocytes with retinoic acid that increases uPA expression (Suzuki et al., 1999); treatment of hASTRO with ATRA increased uPA protein in both FXS and control ACM (Figure 5e). Since our previous studies have shown increased expression of tPA in neural progenitors and brain of Fmr1 KO mice (Achuta et al., 2014), we also measured extracellular levels of tPA that differs in structure from uPA but mediates similar plasminogenic and non-plasminogenic effects in the brain. Levels of tPA were almost undetectable in ACM (less than 300 pg/ml) and tPA amounts did not differ in FXS and control samples (data not shown).
Extracellular uPA levels correlate with intracellular Ca\(^{2+}\) responses in hASTRO

To assess effects of increased uPA on astrocyte function, we studied intracellular Ca\(^{2+}\)\([\text{Ca}^{2+}]_i\) responses of FXS hASTRO using Fura-2-based ratiometric Ca\(^{2+}\) measurements. As shown previously (Cheli et al., 2016), elevated external potassium (17 and 70 mM [K\(^+\)]) induced plasma membrane depolarization and Ca\(^{2+}\) influx via voltage-gated calcium channels (VGCCs) seen as a transient increase that was followed by a slow decline of [Ca\(^{2+}\)]\(_i\) concentrations (Figure 6a). The transient [Ca\(^{2+}\)]\(_i\) responses of cells in hASTRO cultures were relatively uniform in shape and size, suggesting high purity of astrocyte cultures. The specific L-type VGCC inhibitor nifedipine blocked the response (Figure 6a), indicating that the rise in [Ca\(^{2+}\)]\(_i\) was caused by Ca\(^{2+}\) influx via L-type VGCCs.

In FXS hASTRO, the average amplitude of [Ca\(^{2+}\)]\(_i\) responses to elevated [K\(^+\)]\(_e\) was smaller (79% of controls; \(p < .001\)) than that in control hASTRO (Figure 6b). Also the proportion of cells showing [Ca\(^{2+}\)]\(_i\) response was reduced (42% of controls; \(p = .034\)) in FXS hASTRO (Figure 6c). We found a strong correlation between the uPA amount in ACM and the proportion of cells responding to elevated [K\(^+\)]\(_e\) (\(R^2 = 0.786, p = .003\)) (Figure 6d). Data obtained from altogether seven hiPSC lines showed that the higher the level of uPA was in ACM, the smaller the proportion of cells responsive to stimulation. An increase in [Ca\(^{2+}\)]\(_i\) response to elevated [K\(^+\)]\(_e\) after treatment with uPA antibody supported correlation between uPA/uPAR and L-type VGCC-mediated astrocytic calcium signaling (Figure 6e). The proportion of cells with [Ca\(^{2+}\)]\(_i\) response to ATP (100 \(\mu\)M) and the average amplitude of ATP responses did not differ in FXS and control hASTRO (Figure 6f), supporting specificity of altered responses to elevated [K\(^+\)]\(_e\) in FXS cells. Our results demonstrating that an increase in uPA/uPAR signaling in FXS hASTRO associated with reduced functional responses to elevated [K\(^+\)]\(_e\) suggested a critical role for uPA in control of astrocyte function in FXS.

Increased extracellular urokinase modulates neuronal plasticity

To elucidate consequences of increased uPA expression in FXS hASTRO, we investigated potential modulatory effects of increased extracellular uPA on neuronal function and thereby possible pro-maturational effects upon developing networks. Previous studies have shown that binding of neuronal uPA to astrocytic uPAR can activate astrocytes and promote neurological recovery after a hypoxic insult in vivo (Yepes, 2020). To test the neuronal effects of extracellular uPA, we exposed cultured rat primary cortical neurons to ACM collected from FXS and control hASTRO cultures and assessed the phosphorylation of TrkB neurotrophin receptors using ELISA. FXS ACM increased the phosphorylation of the phospholipase-C\(_Y\)1 (PLC\(_Y\)1)-binding tyrosine within the TrkB (TrkB\(^{Tyr156}\)) (interaction: \(F(2.90) = 7.318, p = .0011\); Figure 7a), but left the Shc binding site (TrkB\(^{Tyr155}\)) unaffected (F(2.90) = 0.3119, \(p = .7328\); Figure 7b) in neurons when compared with the effects of control ACM. Treatment with uPA antibody prevented the increase in TrkB\(^{Tyr156}\) phosphorylation,
indicating that neuronal effects were mediated through uPA/uPAR signaling. Indeed, treatment with recombinant rat uPA (5 ng/ml) at the concentration range of FXS hASTRO medium increased the phosphorylation of TrkB (F(1.44) = 33.98, p < .0001; Figure 7c). Treatment with antibody against TrkB ligand binding domain (TrkB.Fc) did not normalize the increase in neuronal TrkB phosphorylation (Figure 7a), suggesting that uPA enhanced responsiveness of TrkB receptors. Our results showing uPA/uPAR-mediated neuronal effects are in agreement with previous studies that have found stimulation of neuronal migration and axon growth by uPA/uPAR signaling (Yepes, 2020).

**FIGURE 5** Increased expression of uPA in FXS compared with controls. 
(a) Gene set enrichment analysis revealed increased expression of genes encoding proteins involved in plasminogen system in FXS hASTRO compared with isogenic control at D95. (b) Expression of PLAU, PLAUR, PLAT, SERPINE1, SERPINE2, and SERPINE3 in the transcriptome data of FXS and control isogenic cells at D12 (n = 3), D60 (n = 3), and D95 hASTRO (n = 2) relative to D0 during astrocyte differentiation. Abbreviation of the encoded protein is shown in parentheses. (c) Expression of PLAU and PLAUR mRNA and (d) the ratio of PLAU to PLAUR mRNA expression in D95 hASTRO generated from FXS hiPSCs compared with appropriate controls (N = 3 FXS and 3 control cell lines). (e) Abundance of uPA protein in astrocyte conditioned medium (ACM) collected from control and FXS hASTRO under basal conditions and after treatment with all-trans retinoic acid (ATRA) treatment (N = 4 FXS and 3 control cell lines). Data in boxplots show the median, the first and third quartiles, and the maximum and minimum values. Student’s t test, *p < 0.05

**DISCUSSION**

Comparison of human astrocytes derived from FXS and control hiPSCs revealed increased expression of uPA in FXS astrocytes and their secretome, which associated with altered astrocytic gene expression linked to uPA/uPAR signaling and reduced [Ca^{2+}], responses via L-type VGCCs. The data suggested that uPA-mediated effects were critical for astrocyte responsiveness. Furthermore, increased uPA in ACM collected from FXS astrocyte cultures augmented phosphorylation of TrkB within the PLCγ1 site in cortical neurons, indicating a role for uPA/uPAR signaling in the regulation of neuronal plasticity. The results demonstrated that uPA is an important regulator of astrocyte-neuron interactions, and that in the absence of FMRP altered uPA/uPAR signaling can modify properties of astrocytes and neuronal function. Previous studies provide evidence of cell type-specific changes, including abnormalities of BDNF/TrkB signaling and calcium dynamics, during differentiation of FMRP-deficient progenitors (Achuta et al., 2018; Achuta et al., 2017; Boland et al., 2017; Louhivuori et al., 2011; Telias et al., 2015; Utami et al., 2020). The uPA-mediated astrocytic mechanisms could serve as critical regulatory
FIGURE 6  Intracellular calcium responses in human FXS and control hASTRO. (a) Representative cell responses in intracellular \([\text{Ca}^{2+}]_{i}\) concentration after stimulation with high (17 and 70 \(\mu M\)) extracellular potassium \([\text{K}^+]_{e}\) in hiPSC-derived D95 astrocytes (hASTRO). Nifedipine that is a specific inhibitor of L-type voltage-gated calcium channels blocked the response. Each trace corresponds to a single cell and the arrows indicate the time of high \([\text{K}^+]_{e}\), and nifedipine (10 \(\mu M\)) addition. (b) The average amplitude of \([\text{Ca}^{2+}]_{i}\) responses, calculated from the responding cells expressed as a percentage of change of the emission intensities, and (c) the proportion of cells that showed \([\text{Ca}^{2+}]_{i}\) response to elevated \([\text{K}^+]_{e}\) in FXS and control hiPSC-derived hASTRO. \(N = 4\) FXS and 4 controls. (d) Correlation of the amount of uPA in astrocyte conditioned medium and the number of cells responding to plasma membrane depolarization with elevated \([\text{K}^+]_{e}\) in control and FXS hASTRO. (e) Effects of uPA antibody treatment (1:2000) on the average amplitude of \([\text{Ca}^{2+}]_{i}\) responses to elevated \([\text{K}^+]_{e}\) in control (HEL23.3) and FXS (HEL70.6) hASTRO. (f) The average amplitude of \([\text{Ca}^{2+}]_{i}\) responses, calculated from the responding cells expressed as a percentage of change of the emission intensities, and the proportion of cells with \([\text{Ca}^{2+}]_{i}\) response to 100 \(\mu M\) ATP in FXS and control hiPSC-derived hASTRO. \(N = 4\) FXS and 4 controls. Responses of 75–100 cells were measured in each experiment. Data are means ± SEM. Mann–Whitney–Wilcoxon test, ***p < 0.001

FIGURE 7  Effects of FXS astrocyte conditioned medium on TrkB receptor phosphorylation in neurons. Phosphorylation of (a) TrkBY816 and (b) TrkBY515 in primary rat cortical neurons treated with medium collected from FXS and control hiPSC-derived astrocyte cultures is shown under basal conditions (ctrl; white circles) and after treatment with antibody against ligand binding domain of TrkB (TrkB.Fc; blue) or with uPA antibody (red). \(N = 4\) FXS and 3 control hiPSC cell lines. (c) Phosphorylation of TrkBY816 in primary rat cortical neurons treated with recombinant rat uPA. Data are means ± SEM. Two-way ANOVA and Fisher’s LSD, ***p < 0.001
mechanisms maintaining cellular homeostasis that is compromised in the absence of FMRP, but they may also provide cellular feedback loop linked to neuronal BDNF/TrkB signaling (Louhivuori et al., 2011), which when dysregulated, could contribute to impaired neuronal plasticity and the phenotype of FXS.

The absence of FMRP altered the expression of several genes leading to FXS-specific changes during sequential differentiation of neural progenitors to functional astrocytes. However, the number of differentially expressed genes in FXS hASTRO at D95 of differentiation was limited to 81 genes when compared to controls. Abnormalities in the plasminogen system, especially related to uPA/uPAR emerged clearly in FXS hASTRO. Our data suggest that astrocytic uPA/uPAR signaling could provide an essential regulatory mechanism that convey messages from extracellular space to define functional properties of both astrocytes and neurons. Upon binding to its receptor, uPA catalyzes the conversion of plasminogen to plasmin on the cell surface, but uPAR also is able to engage in multiple protein/protein interactions (Blasi & Carmeliet, 2002). Since uPAR is devoid of a transmembrane and cytoplasmic domain, it needs a transmembrane partner to activate intracellular signaling. Integrins, G-protein receptors, and caveolin are mediators of uPA/uPAR signaling (Blasi & Carmeliet, 2002). We observed that increased uPA/uPAR signaling in FXS hASTRO associated with activated integrin function, consistent with coordinated actions of uPAR and integrins. The differentially regulated genes in FXS hASTRO included the ADGRA2 gene encoding GPR124. This orphan receptor functions as a WNT7A/WNT7B-specific coactivator of canonical β-catenin signaling (Posokhova et al., 2015) and could potentially act as a transmembrane adaptor of uPAR and contribute to augmented activation of WNT signaling pathways observed in FXS hASTRO. WNT signaling regulates the differentiation of neural progenitors and the formation of neuronal circuits, playing roles in dendrite, and axon development (Oliva et al., 2018). Given that activation of WNT/β-catenin signaling can repress astrocyte specification (Sun et al., 2019), augmented WNT signaling together with reduced functional responses through L-type VGCCs in FXS hASTRO may indicate that lack FMRP affects specification astrocytes.

Both uPA and uPAR are developmentally regulated and their expression declines after peaking at the postnatal period to low or undetectable levels in the normal adult brain (Del Bigio et al., 1999). A transient increase of astrocytic uPAR is seen after cerebral ischemia (Yepes, 2020). In addition, involvement of the plasminogen system and uPA/uPAR signaling has been reported in brain tumors, multiple sclerosis, Alzheimer’s disease, epilepsy, and developmental brain malformations (Akenami et al., 1997; Baart et al., 2020; Gveric et al., 2001; Iyer et al., 2010; Liu et al., 2010). Furthermore, a genetic link between the PLAUR gene and autism has been established integrated with MET signaling (Campbell et al., 2008). Involvement of uPAR in ASD was indicated by increased PLAUR mRNA expression in the postmortem ASD brain. The present study connected alterations of uPA/uPAR signaling with FXS, the most common genetic cause of ASD. The regulatory role of astrocytes in uPA/uPAR signaling and correlations of uPA levels with functional properties of astrocytes have not been previously described and our data provide novel insights to basic cellular mechanisms that could be disrupted in several forms of ASD. Impact of uPAR signaling in the developmental processes that define the adaptive capacity of cortical circuits was previously demonstrated in transgenic mice with genetic deletion of uPAR resulting in a reduced number of parvalbumin interneurons (Eagleson et al., 2010). Thus, uPA/uPAR signaling could contribute to synaptic excitation and inhibition balance that is affected in FXS and in many neurodevelopmental disorders (Gibson et al., 2008). Increased uPA/uPAR signaling in FXS hASTRO may reflect the abnormality and inability of astrocytes lacking FMRP to provide the normal neuronal support needed. Indeed, previous studies have demonstrated that coculturing of Fmr1 KO mouse neurons with wild type mouse astrocytes shows rescue effects on the neuronal phenotype caused by FMRP deficiency (Jacobs & Doering, 2010).

Astrocytes comprise morphologically and functionally diverse populations of cells with brain region-specific differences in their properties. The differentiation method we employed produced homogenous cultures of human forebrain astrocytes expressing canonical astrocytic markers. The hASTRO were functional, as demonstrated by using intracellular calcium recordings, and allowed investigation of the innate properties of FXS astrocytes.

Astrocytes are crucial for synaptic and neuronal network formation and function, maintenance of brain homeostasis, and response to injury and repair. The astrocyte secretome illustrates astrocytic function. Rat primary cortical neurons were well suited for screening of the neuronal effects of FXS astrocyte secretome. Using a standardized method, murine primary neuronal cultures can be produced with minimal contribution of nonneuronal cells in a reliable and reproducible manner (Sahu et al., 2019). Since neurons do not divide in culture and they can be maintained for a limited period in culture, primary cortical, and hippocampal cultures need to be generated from embryonic or early postnatal brain regions every time. Neuronal differentiation from stem cells, an unlimited source of progenitors, is current option that also allows generation of human neurons. Functional neurons can be differentiated from hiPSCs or fibroblast-direct conversion, but there are some variation in the differentiation efficiency depending on the used differentiation protocol. Effects of FXS hASTRO secretome remain to be validated in hiPSC-derived human neuronal cultures. Altered functional maturation of FXS hASTRO and effects of FXS hASTRO secretome on TrkB signaling in rat neurons suggested that astrocytes have a significant impact on neuronal network formation and function in FXS. Therefore, understanding of the special role of astrocytes in the FXS brain is important for the success of treatment strategies.

ACKNOWLEDGMENTS
We would like to thank the DNA Sequencing and Genomics Laboratory at the Institute of Biotechnology for the RNA sequencing analysis and Pia Laine together with Petri Auvinen for assisting with the data analysis. Imaging experiments were performed using services of the Biomedicum Imaging Unit. We also thank the Director of the Neuroscience Center Jari Koistinaho for the control hiPSC cell lines. The work...
was supported by the Academy of Finland, the Arvo and Lea Ylppö Foundation, the Finnish Konkordia Fund, the Finnish Cultural Foundation, the Finnish Brain Foundation, the Finnish Foundation for Pediatric Research, and the FRAXA Research Foundation. MAP is Michael Smith Foundation for Health Research Scholar.

AUTHOR CONTRIBUTION

Maija L. Castrén conceived the project and was responsible for project administration. Ulla-Kaisa Peteri generated astrocytes and performed most of the experiments. Laurent Roybon and Plinio Casorotto participated in the implementation of astrocyte differentiation and TrkB experiments, respectively. Tomas M. Strandin and Antti Vaheri helped with immunoassays. Juho Pitkonen analyzed data with assistance of Otso Nieminen. Ilario de Toma and Padraic Corcoran performed bioinformatics analyzes. Kagišta Hana Utami and Mahmoud A. Pouladi Otso Nieminen. Ilario de Toma and Padraic Corcoran performed bioinformatics analyzes. Kagišta Hana Utami and Mahmoud A. Pouladi

The data that support the findings of this study are available from the DATA AVAILABILITY STATEMENT

Maija L. Castrén wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

CONFLICT OF INTEREST

The authors declare no potential conflict of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Juho Pitkonen https://orcid.org/0000-0002-4633-3578
Maija L. Castrén https://orcid.org/0000-0002-9644-5295

REFERENCES

Achuta, V. S., Möykkynen, T., Peteri, U.-K., Turconi, G., Rivera, C., Keinänen, K., & Castren, M. L. (2018). Functional changes of AMPA responses in human induced pluripotent stem cell-derived neural progenitors in autism spectrum disorder. Science Signaling, 11, 1–11. https://doi.org/10.1126/scisignal.aan8784

Achuta, V. S., Putkonen, P., Grym, H., Louhivuori, V., Kärkkäinen, V., & Castrén, M. L. (2017). Metabotropic glutamate receptor 5 responses dictate differentiation of neural progenitors to NMDA-responsive cells in fragile X syndrome. Developmental Neurobiology, 4, 438–453. https://doi.org/10.1002/dneu.22419

Achuta, V. S., Rezov, V., Uutela, M., Louhivuori, V., Louhivuori, L., & Castrén, M. L. (2014). Tissue plasminogen activator contributes to alterations of neuronal migration and activity-dependent responses in fragile X mice. The Journal of Neuroscience, 34, 1916–1923. https://doi.org/10.1523/JNEUROSCI.3753-13.2014

Akenami, F. O. T., Koskineni, M., Mustjoki, S., Sirén, V., Färkkilä, M., & Vaheri, A. (1997). Plasma and cerebrospinal fluid activities of tissue plasminogen activator, urokinase and plasminogen activator inhibitor-1 in multiple sclerosis. Fibrinolysis & Proteolysis, 11, 109–113. https://doi.org/10.1136/jcp.49.7.577

Asikainen, S., Heikkinen, L., Juhila, J., Holm, F., Weltner, J., Trokovic, R., Mikkola, M., Toivonen, S., Balboa, D., Lampela, R., Icy, K., Tuuri, T., Otonkoski, T., Wong, G., & Hovatta, O. (2015). Selective microRNA-offset RNA expression in human embryonic stem cells. PLoS One, 10, e0116668. https://doi.org/10.1371/journal.pone.0116668

Baart, V. M., Houvast, R. D., de Geus-Oei, L. F., Quax, P. H. A., Kuppen, P. J. K., Vahrmeijer, A. L., & Sier, C. F. M. (2020). Molecular imaging of the urokinase plasminogen activator receptor: Opportunities beyond cancer. EJNMMI Research, 10, 87. https://doi.org/10.1186/s13550-020-00673-7

Berry-Kravis, E. (2002). Epilepsy in fragile X syndrome. Developmental Medicine and Child Neurology, 44, 724–728. https://doi.org/10.1017/s0012162201002833

Blasi, F., & Carmeliet, P. (2002). uPAR: A versatile signalling orchestrator. Nature Reviews Molecular Cell Biology, 3, 932–943. https://doi.org/10.1038/nrm7977

Boland, M. J., Nazor, K. L., Tran, H. T., Szücs, A., Lynch, C. L., Paredes, R., Tassone, F., Sanna, P. P., Hagerman, R. J., & Loring, J. F. (2017). Molecular analyses of neurogenic defects in a pluripotent stem cell model of fragile X syndrome. Brain, 40, 582–598. https://doi.org/10.1093/brain/awx335

Campbell, D. B., Li, C., Sutcliffe, J. S., Persico, A. M., & Levitt, P. (2008). Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder. Autism Research, 1, 159–168. https://doi.org/10.1002/aur.27

Campbell, D. B., Sutcliffe, J. S., Ebert, P. J., Militeri, R., Bravaccio, C., Trillo, S., Elia, M., Schneider, C., Melmed, R., Sacco, R., Persico, A. M., & Levitt, P. (2006). A genetic variant that disrupts MET transcription is associated with autism. Proceedings of the National Academy of Sciences of the United States of America, 103, 16834–16839. https://doi.org/10.1073/pnas.0605296103

Casingal, C. R., Kikkawa, T., Inada, H., Sasaki, Y., & Osumi, N. (2020). Identification of FMRP target mRNAs in the developmental brain: FMRP might coordinate Ras/MAPK, Wnt/beta-catenin, and mTOR signaling during corticogenesis. Molecular Brain, 13, 167. https://doi.org/10.1186/s13041-020-00706-1

Chelli, V. T., Santiago González, D. A., Smith, J., Spreuer, V., Murphy, G. G., & Paez, P. M. (2016). L-type voltage-operated calcium channels contribute to astrocyte activation in vitro. Glia, 64, 1396–1415. https://doi.org/10.1002/glia.23013

Cheng, C., Lau, S. K. M., & Doering, L. C. (2016). Astrocyte-secreted thrombospondin-1 modulates synapse and spine defects in the fragile X mouse model. Molecular Brain, 9, 74. https://doi.org/10.1186/s13041-016-0256-9

Colak, D., Zaninovic, N., Cohen, M. S., Rosenwaks, Z., Yang, W. Y., Gerhardt, J., Disney, M. D., & Jaffrey, S. R. (2014). Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. Science, 343, 1002–1005. https://doi.org/10.1126/science.1245831

Crawford, D. C., Meadows, K. L., Newman, J. L., Taft, L. F., Pettay, D. L., Gold, L. B., Hersey, S. J., Hinkle, E. F., Stanfield, M. L., Holmgren, P., Yearin-Allsopp, M., Boyle, C., & Sherman, S. L. (1999). Prevalence and phenotype consequence of FRAXA and FRAXE alleles in a large, ethnically diverse, special education-needs population. American Journal of Human Genetics, 64, 495–507. https://doi.org/10.1086/302260

Del Bigio, M. R., Hosain, S., & Altumbabic, M. (1999). Localization of urokinase plasminogen activator (uPAR) promotes astrocytic activation and synaptic recovery in the ischemic brain. The Journal of Neuroscience, 19, 17–24. https://doi.org/10.1523/JNEUROSCI.17-01-1999.1703

Diaz, A., Merino, P., Manrique, L. G., Ospina, J. P., Wu, L. C. F., Jeanneret, V., & Yepes, M. (2017). A cross talk between neuronal urokinase-type plasminogen activator (uPA) and astrocytic uPA receptor (uPAR) promotes astrocytic activation and synaptic recovery in the ischemic brain. The Journal of Neuroscience, 37, 10310–10322. https://doi.org/10.1523/JNEUROSCI.1630-17.2017

Durkee, C. A., & Araque, A. (2019). Diversity and specificity of astrocyteneuron communication. Neuroscience, 396, 73–78. https://doi.org/10.1016/j.neuroscience.2018.11.010
Eagleson, K. L., Graville, M. C., SchluechterMcFadyen-Ketchum, L. J., Russek, S. J., Farb, D. H., & Levitt, P. (2010). Genetic disruption of the autism spectrum disorder risk gene PLAUR induces GABAA receptor subunit changes. *Neuroscience, 168*, 797–810. https://doi.org/10.1016/j.neuroscience.2010.03.066

Fred, S. M., Laukkanen, L., Brunello, C. A., Vesa, L., Göös, H., Cardon, I., Moliner, R., Maritzen, T., Varjosalo, M., Casarotto, P. C., & Castrén, E. (2019). Pharmacologically diverse antidepressants facilitate TRKB receptor activation by disrupting its interaction with the endocytic adaptor complex AP-2. *Journal of Biological Chemistry, 294*, 18150–18161. https://doi.org/10.1074/jbc.R1A19.008837

Gibson, J. R., Bartley, A. F., Hays, S. A., & Huber, K. M. (2008). Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. *Journal of Neurophysiology, 100*, 2615–2626. https://doi.org/10.1152/jn.90752.2008

Gveric, D., Hanemaaijer, R., Newcombe, J., van Lent, N. A., Sier, C. F., & PETERI ET AL. (2016). The Val66Met polymorphism in the BDNF gene is associated with epilepsy in fragile X syndrome. *Epilepsy Research, 85*, 114–117. https://doi.org/10.1016/j.eplepsyres.2009.01.005

Lindner, J., Guenther, J., Nick, H., Zismer, G., Antonieck, H., Schachner, M., & Monard, D. (1986). Modulation of granule cell migration by a glia-derived protein. *Proceedings of the National Academy of Sciences of the United States of America, 83*, 4568–4571. https://doi.org/10.1073/pnas.83.12.4568

Liu, B., Zhang, B., Wang, T., Liang, Q. C., Jing, X. R., Zheng, J., Wang, C., Meng, Q., Wang, L., Wang, W., Guo, H., You, Y., Zhang, H., & Gao, G. D. (2010). Increased expression of uronosine-type-protein activator receptor in the frontal cortex of patients with intractable frontal lobe epilepsy. *Journal of Neuroscience Research, 88*, 2747–2754. https://doi.org/10.1002/jnr.22419

Loizou, V., Arvio, M., Soronen, P., Oksanen, V., Paunio, T., & Castrén, M. L. (2009). The Val66Met polymorphism in the BDNF gene is associated with epilepsy in fragile X syndrome. *Epilepsy Research, 85*, 114–117. https://doi.org/10.1016/j.eplepsyres.2009.01.005

Luo, Y., Shan, G., Guo, W., Smrt, R. D., Johnson, E. B., Li, X., Pfeiffer, R. L., Szulwach, K. E., Duan, R., Barkho, B. Z., Li, W., Liu, C., Jin, P., & Zhao, X. (2010). Fragile X mental retardation protein regulates proliferation and differentia- lization of adult neural stem/progenitor cells. *PLoS Genetics, 6*, e1000898. https://doi.org/10.1371/journal.pgen.1000898

Magistri, M., Khoury, N., Mazza, E. M. C., Velmeshev, D., Lee, J. K., Bicciato, S., Tsoufas, P., & Faghihi, M. A. (2016). A comparative transcrip- tomy analysis of astrocytes differentiation from human neural pro- genitor cells. *The European Journal of Neuroscience, 44*, 2858–2870. https://doi.org/10.1111/ejn.13382

Molofsky, A. V., Krenick, R., Ullian, E. M., Tsai, H., Deneen, B., Richardson, W. D., Barres, B. A., & Rowitch, D. H. (2012). Astrocytes and disease: A neurodevelopmental perspective. *Genes & Development, 26*, 891–907. https://doi.org/10.1101/gad.183826.112

Molofsky, A. V., Krenick, R., Ullian, E. M., Tsai, H., Deneen, B., Richardson, W. D., Barres, B. A., & Rowitch, D. H. (2012). Astrocytes and disease: A neurodevelopmental perspective. *Genes & Development, 26*, 891–907. https://doi.org/10.1101/gad.183826.112

Oliva, C. A., Montecinos- Oliva, C., & Inestrosa, N. C. (2018). Wnt signaling in the central nervous system: New insights in health and disease. *Progress in Molecular Biology and Translational Science, 153*, 81–130. https://doi.org/10.1016/b978-0-12-816921-5.00004-9

Peteri, U., Ptikonen, J., Utami, K. H., Paavola, J., Raybon, L., Pouladi, M., & Castrén, M. L. (2020). Generation of the human pluripotent stem-cell- derived astrocyte model with forebrain identity. *Brain Sciences, 11*, 209. https://doi.org/10.3390/brainsci11020209

Posokhova, E., Shukla, A., Seaman, S., Volate, S., Hilton, M. B., Wu, B., Morris, H., Swing, D. A., Zhou, M., Zudaire, E., Rubin, J. S., & St Croix, B. (2015). GPR124 functions as a WNT7-specific coactivator of canonical β-catenin signaling. *Cell Reports, 10*, 123–130. https://doi.org/10.1016/j.celrep.2014.12.020

Raudvere, U., Kolberg, L., Kuzmin, I., Arak, T., Adler, P., Peterson, H., & Vilo, J. (2019). G-Profiler: A web server for functional enrichment analysis and conversions of gene lists (2019 update). *Nucleic Acids Research, 47*, W191–W198. https://doi.org/10.1093/nar/gkz369

Rubenstein, J. L., Shimamur, K., Martínez, S., & Puelles, L. (1998). Regionalization of the prosencephalic neural plate. *Annual Review of Neuroscience, 21*, 445–477. https://doi.org/10.1146/annurev.neuro.21.1.445

Russ, K., Teku, G., Bousset, L., Redeker, V., Piel, S., Savchenko, E., Pomeschik, Y., Savistchenko, J., Stummann, T. C., Azevedo, C., Collin, A., Goldwurm, S., Fog, K., Elmer, E., Vihinen, M., Melki, R., & Roybon, L. (2021). TNF-α and α-synuclein fibrils differently regulate human astrocyte immune reactivity and impair mitochondrial respiration. *Cell Reports, 34*, 108895. https://doi.org/10.1016/j.celrep.2021.108895
